Data supplements
Supplemental Data
Files in this Data Supplement:
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Jump to section
Related Articles
Cited By...
- Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
- Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy
- Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
- Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial
- ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Quo Vadis, Molecular Imaging?
- Can Molecular Imaging Measure T-cell Activation?
- The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment